KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) beta2 agonist (EC50 = 1.9 nM). KCL-286 targets RARbeta2 with good selectivity over RAR alpha (EC50 = 26 nM) and RAR gamma (EC50 = 11 nM). KCL-286 activates RARbeta2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury[1][3].
Molekulargewicht:
334.33
Reinheit:
98.93
CAS Nummer:
[1952276-71-9]
Formel:
C19H14N2O4
Target-Kategorie:
RAR/RXR
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
